Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) Stock Rating Upgraded by Wall Street Zen

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) was upgraded by analysts at Wall Street Zen from a “buy” rating to a “strong-buy” rating in a research note issued on Saturday.

Other research analysts also recently issued reports about the stock. UBS Group downgraded shares of Fresenius Medical Care AG & Co. KGaA from a “sell” rating to an “underperform” rating in a research note on Wednesday, October 15th. Zacks Research upgraded shares of Fresenius Medical Care AG & Co. KGaA from a “hold” rating to a “strong-buy” rating in a report on Monday, October 6th. Morgan Stanley reissued an “underweight” rating on shares of Fresenius Medical Care AG & Co. KGaA in a research report on Tuesday, August 12th. Bank of America downgraded Fresenius Medical Care AG & Co. KGaA from a “neutral” rating to an “underperform” rating in a research note on Wednesday, October 15th. Finally, Weiss Ratings upgraded Fresenius Medical Care AG & Co. KGaA from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Wednesday, October 8th. One research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, one has assigned a Hold rating and three have given a Sell rating to the company’s stock. According to MarketBeat, Fresenius Medical Care AG & Co. KGaA has a consensus rating of “Hold” and a consensus target price of $27.80.

Fresenius Medical Care AG & Co. KGaA Trading Up 1.4%

FMS stock opened at $27.29 on Friday. The company has a current ratio of 1.44, a quick ratio of 1.08 and a debt-to-equity ratio of 0.44. Fresenius Medical Care AG & Co. KGaA has a 1 year low of $18.94 and a 1 year high of $30.46. The stock has a 50-day simple moving average of $25.88 and a 200-day simple moving average of $26.46.

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) last released its quarterly earnings results on Tuesday, August 5th. The company reported $0.52 earnings per share for the quarter, topping analysts’ consensus estimates of $0.50 by $0.02. Fresenius Medical Care AG & Co. KGaA had a return on equity of 6.75% and a net margin of 3.39%.The firm had revenue of $5.54 billion during the quarter, compared to analysts’ expectations of $5 billion. Sell-side analysts forecast that Fresenius Medical Care AG & Co. KGaA will post 1.51 EPS for the current year.

Hedge Funds Weigh In On Fresenius Medical Care AG & Co. KGaA

Hedge funds have recently bought and sold shares of the company. Crossmark Global Holdings Inc. boosted its holdings in Fresenius Medical Care AG & Co. KGaA by 0.9% in the first quarter. Crossmark Global Holdings Inc. now owns 64,871 shares of the company’s stock worth $1,615,000 after purchasing an additional 584 shares during the period. GAMMA Investing LLC lifted its position in shares of Fresenius Medical Care AG & Co. KGaA by 5.9% in the 3rd quarter. GAMMA Investing LLC now owns 10,437 shares of the company’s stock worth $275,000 after buying an additional 585 shares during the last quarter. Yousif Capital Management LLC boosted its holdings in shares of Fresenius Medical Care AG & Co. KGaA by 6.8% in the 2nd quarter. Yousif Capital Management LLC now owns 9,804 shares of the company’s stock valued at $280,000 after buying an additional 625 shares during the period. Callan Capital LLC grew its position in shares of Fresenius Medical Care AG & Co. KGaA by 6.6% during the 1st quarter. Callan Capital LLC now owns 13,974 shares of the company’s stock valued at $348,000 after buying an additional 870 shares during the last quarter. Finally, Russell Investments Group Ltd. grew its position in shares of Fresenius Medical Care AG & Co. KGaA by 21.3% during the 2nd quarter. Russell Investments Group Ltd. now owns 5,096 shares of the company’s stock valued at $146,000 after buying an additional 896 shares during the last quarter. 8.37% of the stock is currently owned by institutional investors and hedge funds.

Fresenius Medical Care AG & Co. KGaA Company Profile

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.